Engineered butyrate-producing bacteria prevents high fat diet-induced obesity in mice.
Butyric acid
Engineered bacteria
Fecal metabolomics
High-fat diet
Obesity
Journal
Microbial cell factories
ISSN: 1475-2859
Titre abrégé: Microb Cell Fact
Pays: England
ID NLM: 101139812
Informations de publication
Date de publication:
25 Apr 2020
25 Apr 2020
Historique:
received:
08
02
2020
accepted:
13
04
2020
entrez:
27
4
2020
pubmed:
27
4
2020
medline:
31
12
2020
Statut:
epublish
Résumé
Obesity is a major problem worldwide and severely affects public safety. As a metabolite of gut microbiota, endogenous butyric acid participates in energy and material metabolism. Considering the serious side effects and weight regain associated with existing weight loss interventions, novel strategies are urgently needed for prevention and treatment of obesity. In the present study, we engineered Bacillus subtilis SCK6 to exhibited enhanced butyric acid production. Compared to the original Bacillus subtilis SCK6 strain, the genetically modified BsS-RS06550 strain had higher butyric acid production. The mice were randomly divided into four groups: a normal diet (C) group, a high-fat diet (HFD) group, an HFD + Bacillus subtilis SCK6 (HS) group and an HFD + BsS-RS06550 (HE) group. The results showed BsS-RS06550 decreased the body weight, body weight gain, and food intake of HFD mice. BsS-RS06550 had beneficial effects on blood glucose, insulin resistance and hepatic biochemistry. After the 14-week of experiment, fecal samples were collected for nontargeted liquid chromatography-mass spectrometry analysis to identify and quantify significant changes in metabolites. Sixteen potentially significant metabolites were screened, and BsS-RS06550 was shown to potentially regulate disorders in glutathione, methionine, tyrosine, phenylalanine, and purine metabolism and secondary bile acid biosynthesis. In this study, we successfully engineered Bacillus subtilis SCK6 to have enhanced butyric acid production. The results of this work revealed that the genetically modified live bacterium BsS-RS06550 showed potential anti-obesity effects, which may have been related to regulating the levels of metabolites associated with obesity. These results indicate that the use of BsS-RS06550 may be a promising strategy to attenuate obesity.
Sections du résumé
BACKGROUND
BACKGROUND
Obesity is a major problem worldwide and severely affects public safety. As a metabolite of gut microbiota, endogenous butyric acid participates in energy and material metabolism. Considering the serious side effects and weight regain associated with existing weight loss interventions, novel strategies are urgently needed for prevention and treatment of obesity.
RESULTS
RESULTS
In the present study, we engineered Bacillus subtilis SCK6 to exhibited enhanced butyric acid production. Compared to the original Bacillus subtilis SCK6 strain, the genetically modified BsS-RS06550 strain had higher butyric acid production. The mice were randomly divided into four groups: a normal diet (C) group, a high-fat diet (HFD) group, an HFD + Bacillus subtilis SCK6 (HS) group and an HFD + BsS-RS06550 (HE) group. The results showed BsS-RS06550 decreased the body weight, body weight gain, and food intake of HFD mice. BsS-RS06550 had beneficial effects on blood glucose, insulin resistance and hepatic biochemistry. After the 14-week of experiment, fecal samples were collected for nontargeted liquid chromatography-mass spectrometry analysis to identify and quantify significant changes in metabolites. Sixteen potentially significant metabolites were screened, and BsS-RS06550 was shown to potentially regulate disorders in glutathione, methionine, tyrosine, phenylalanine, and purine metabolism and secondary bile acid biosynthesis.
CONCLUSIONS
CONCLUSIONS
In this study, we successfully engineered Bacillus subtilis SCK6 to have enhanced butyric acid production. The results of this work revealed that the genetically modified live bacterium BsS-RS06550 showed potential anti-obesity effects, which may have been related to regulating the levels of metabolites associated with obesity. These results indicate that the use of BsS-RS06550 may be a promising strategy to attenuate obesity.
Identifiants
pubmed: 32334588
doi: 10.1186/s12934-020-01350-z
pii: 10.1186/s12934-020-01350-z
pmc: PMC7183672
doi:
Substances chimiques
Butyrates
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
94Subventions
Organisme : National Key Research and Development Project
ID : 2019YFA0905600
Organisme : Science and Technology Program of Tianjin, China
ID : 19YFSLQY00110
Organisme : Natural Science Foundation of Tianjin, China
ID : 19JCTPJC40900
Références
PLoS Med. 2018 Oct 10;15(10):e1002670
pubmed: 30303968
Cell Syst. 2018 Jul 25;7(1):5-16
pubmed: 30048620
Nature. 2019 Aug;572(7771):614-619
pubmed: 31435015
Gut. 2018 Jul;67(7):1269-1279
pubmed: 29101261
Clin Chim Acta. 2017 Oct;473:89-95
pubmed: 28842175
JCI Insight. 2019 Jun 20;4(12):
pubmed: 31217353
J Agric Food Chem. 2019 Apr 3;67(13):3624-3632
pubmed: 30832480
Curr Opin Lipidol. 2015 Dec;26(6):536-43
pubmed: 26382553
J Bacteriol. 2004 Apr;186(7):2099-106
pubmed: 15028695
Microb Biotechnol. 2011 Jan;4(1):98-105
pubmed: 21255377
Mar Drugs. 2017 Aug 30;15(9):
pubmed: 28867763
Nutrients. 2019 May 06;11(5):
pubmed: 31064150
Am J Clin Nutr. 2020 Mar 1;111(3):545-554
pubmed: 31927581
Gastroenterology. 2018 Aug;155(2):501-513
pubmed: 29689264
Biochem Pharmacol. 2002 Jun 1;63(11):2011-8
pubmed: 12093478
Curr Opin Microbiol. 2013 Jun;16(3):255-61
pubmed: 23831042
Inflammopharmacology. 2018 Aug;26(4):1051-1055
pubmed: 29633106
Aliment Pharmacol Ther. 2019 Mar;49(5):506-515
pubmed: 30746776
Nat Biotechnol. 2018 Oct;36(9):857-864
pubmed: 30102294
BMC Bioinformatics. 2016 Apr 19;17:172
pubmed: 27094401
Proc Natl Acad Sci U S A. 2010 Sep 14;107(37):16286-90
pubmed: 20805502
Lancet Diabetes Endocrinol. 2018 Mar;6(3):161-163
pubmed: 29329974
Microb Cell Fact. 2020 Jan 28;19(1):15
pubmed: 31992268
Nutrients. 2017 Jul 17;9(7):
pubmed: 28714911
Nat Rev Endocrinol. 2018 Sep;14(9):513-537
pubmed: 30065268
Lancet Public Health. 2018 Oct;3(10):e490-e497
pubmed: 30177479
J Nutr Biochem. 2018 Nov;61:68-81
pubmed: 30189365
Sci Transl Med. 2019 Jan 16;11(475):
pubmed: 30651324
Anim Sci J. 2018 Jun;89(6):895-905
pubmed: 29603498
J Food Sci. 2018 Mar;83(3):864-873
pubmed: 29427445
Prog Mol Biol Transl Sci. 2014;121:351-76
pubmed: 24373243
Appl Environ Microbiol. 2015 Apr;81(7):2506-14
pubmed: 25636838
EBioMedicine. 2017 Aug;22:200-207
pubmed: 28655596
Front Microbiol. 2016 Feb 17;7:185
pubmed: 26925050
Lancet. 2014 Aug 30;384(9945):766-81
pubmed: 24880830
Nature. 1997 Nov 20;390(6657):249-56
pubmed: 9384377
Sci Transl Med. 2016 Jan 27;8(323):323rv2
pubmed: 26819198
Sci Rep. 2016 Jun 16;6:27943
pubmed: 27305971
Cell Metab. 2019 Feb 5;29(2):488-500.e2
pubmed: 30318341
Environ Microbiol. 2018 Sep;20(9):3406-3426
pubmed: 30126070
Biomed Res Int. 2015;2015:636249
pubmed: 26881203
J Neurol. 2009 Dec;256(12):2072-8
pubmed: 19633906
Mol Nutr Food Res. 2018 Jul;62(13):e1800274
pubmed: 29762899
J Clin Invest. 2014 Aug;124(8):3391-406
pubmed: 24960158
Diabetologia. 2019 Nov;62(11):2106-2117
pubmed: 31410531
Obesity (Silver Spring). 2018 Feb;26(2):351-361
pubmed: 29280312
Cell. 2016 Jun 2;165(6):1332-1345
pubmed: 27259147
Sci Rep. 2018 Aug 8;8(1):11874
pubmed: 30089798
Sci Rep. 2017 Mar 14;7:44553
pubmed: 28291252
Obes Res. 2005 Jan;13(1):118-22
pubmed: 15761170
Obes Rev. 2018 Apr;19(4):435-451
pubmed: 29363272
Diabetes Metab J. 2012 Feb;36(1):13-25
pubmed: 22363917
J Agric Food Chem. 2019 Jul 3;67(26):7315-7324
pubmed: 31184122
Am J Clin Nutr. 2019 Nov 14;:
pubmed: 31725157